# A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants

> **NCT02015533** · PHASE1 · WITHDRAWN · sponsor: **Janssen Pharmaceutical K.K.**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** CR8020
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02015533
- **Lead sponsor:** Janssen Pharmaceutical K.K.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-12
- **Primary completion:** 2014-01
- **Final completion:** 2014-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated due to an unexpected preliminary result obtained from the study with CR8020.
- **Last updated:** 2019-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02015533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02015533, "A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02015533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*